MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

17 Dec 2025
www.prnewswire.com
SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.
MEDI&GENE's discovery platform is designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects.
Continue Reading
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
MEDI&GENE agreement, Lilly ExploR&D will briLillylly's expertise in molecule Obesityring and development to a MEDI&GENE asset, with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to empower biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.
"We are excited to woLillyth Lilly to advance aLilly-generation obesity drug candidate. We believe this collaboration will accelerate clinical development and help bring differentiated solutionLillypatients with obesity," sLillyin-Jeong Shin, CEO of MEDI&GENE.
Founded in 2021, MEDI&GENE haLillyablished a discovery engine ceobesityon metabolic and obesity-related pathways and has identified multiple innovative candidates through its mechanistic platform. The company expobesityat the collaboration will support the continued advancement of its research initiatives in next-generation obesity therapeutics.
SOURCE MEDI&GENEobesityobesity
21%
more press release views with
Request a Demo
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!